| (Values in U.S. Thousands) | Dec, 2014 | Dec, 2013 | Dec, 2012 | Apr, 2026 | Apr, 2026 |
| Sales | 31,800 | 19,510 | 5,390 | 0 | 0 |
| Sales Growth | +62.99% | +261.97% | unch | unch | unch |
| Net Income | -57,370 | -50,310 | -43,310 | 0 | 0 |
| Net Income Growth | -14.03% | -16.16% | unch | unch | unch |
Trivascular Technologies Inc (TRIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Trivascular Technologies, Inc. is a medical device company. It is developing and commercializing technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms. The company offers ovation system, a stent graft platform for the treatment of AAA through minimally invasive endovascular aortic repair. It is also developing a short-cure fill polymer; next generation iliac limbs; ovation alto system, a next generation aortic body; and other platform applications. TriVascular Technologies, Inc. is headquartered in Santa Rosa, California.
Fiscal Year End Date: 12/31